PRLB Proto Labs 10-Q 2026-06-30 section summaries

Proto Labs, Inc. (PRLB) — Q2 and H1 2026

Revenue, margins and earnings

• Q2 2026: Revenue increased 10.6% to $149.341M from $135.063M. Cost of revenue rose to $79.999M from $75.289M, while gross profit increased to $69.342M from $59.774M. Operating expenses were $57.984M vs. $54.805M; these included $0.924M of restructuring and transformation costs and $0.937M of exit and disposal costs, compared with no restructuring charge and $0.149M of exit and disposal costs in Q2 2025. Operating income more than doubled to $11.358M from $4.969M; net income was $9.152M vs. $4.427M, and diluted EPS was $0.37 vs. $0.18.
• H1 2026: Revenue grew 10.5% to $288.677M from $261.268M. Cost of revenue was $155.743M vs. $145.796M, and gross profit was $132.934M vs. $115.472M. Operating expenses were $111.737M vs. $105.972M, including $2.345M of restructuring and transformation costs and $0.937M of exit and disposal costs. Operating income rose to $21.197M from $9.500M and net income to $17.263M from $8.026M; diluted EPS was $0.71 vs. $0.33. Other income, net, declined to $2.723M from $3.159M.

Q2 revenue mix and segment performance

Growth was led by CNC Machining and Injection Molding, while 3D Printing revenue declined.

U.S. operating performance improved substantially, while Europe’s operating loss widened despite higher revenue. The company also reported Q2 restructuring and transformation costs of $0.924M and exit and disposal costs of $0.937M, both associated with Europe; the comparable Q2 2025 exit and disposal costs were $0.149M.

Balance sheet, liquidity and cash flows

At June 30, 2026, total assets were $791.298M (vs. $763.415M at December 31, 2025), and total shareholders’ equity was $691.733M (vs. $673.932M). Goodwill was $273.991M, unchanged. Intangible assets other than goodwill were $16.606M (vs. $18.612M), comprising $0 of non-compete agreements, $2.052M of software technology and $14.554M of software platform assets. Derived tangible common equity, calculated as equity less goodwill and other intangible assets, was $401.136M.

Cash and cash equivalents were $127.918M (vs. $110.826M). Short- and long-term marketable securities totaled $34.978M fair value (vs. $31.605M); at June 30, securities had $35.147M cost, $0.005M unrealized gains and $0.174M unrealized losses. Total liabilities were $99.565M (vs. $89.483M); the filing reported no material borrowings, with lease liabilities among listed obligations. Net accounts receivable increased to $95.074M from $78.962M, and the credit-loss allowance rose to $3.022M from $2.668M.

H1 operating cash flow was $32.978M vs. $28.963M. Capital expenditures—purchases of property, equipment and other capital assets—were $9.743M vs. $2.730M. Q2 additions to long-lived assets were $6.203M vs. $1.468M, primarily in the U.S. ($5.658M vs. $1.125M); Europe spending was $0.545M vs. $0.343M. Total long-lived assets were $208.329M at June 30, down from $215.261M at year-end. Q2 depreciation and amortization was $8.088M vs. $8.570M.

Capital allocation, awards and other risks

H1 stock repurchases were $5.036M vs. $23.980M; all H1 repurchases occurred in Q2, when 68,553 shares were repurchased for $5.036M. Shares outstanding increased from 23,627,422 at December 31, 2025 to 23,921,897 at June 30, 2026. H1 stock-based compensation was $7.307M vs. $8.251M; diluted weighted-average shares were 24.359M vs. 24.291M.

At June 30, 295,912 options were outstanding (weighted-average exercise price $53.54), including 114,024 exercisable options (weighted-average exercise price $61.44); H1 grants were 73,560 options and exercises were 100,267. The company also had 595,416 RSUs (weighted-average grant-date fair value $47.31) and 235,509 PSUs (weighted-average grant-date fair value $69.29) outstanding. PSU vesting can range from 0% to 200% of target based on three-year relative shareholder returns and continued employment. Unrecognized compensation expense totaled $35.7M—$4.4M for options, $20.5M for RSUs and $10.8M for PSUs—expected to be recognized over weighted-average periods of 3.2, 2.9 and 2.2 years, respectively. Shareholders approved another 395,000 shares for the 2022 incentive plan in May 2026.

The effective tax rate declined to 27.4% in Q2 from 33.7% and 27.8% in H1 from 36.6%, primarily reflecting tax benefits from restricted-stock vesting and option exercises; H1 also benefited from losses at a newly established India entity. Unrecognized tax benefits were $3.2M, compared with $3.1M at year-end; recognition would reduce the effective tax rate. Facility exit and closure impairment was $0.937M in H1, with another $0.186M of equipment impairment. Euro-denominated acquired intangibles create foreign-exchange exposure; related unrealized losses were $0.9M at June 30, 2026 vs. $0.5M at December 31, 2025. Remaining estimated intangible amortization was $16.606M, including $1.790M for the remainder of 2026.

PRLB — Q2 and H1 2026 MD&A

Revenue, margins and earnings

Q2 2026 revenue increased 10.6% to $149.341M from $135.063M. Cost of revenue rose 6.3% to $79.999M from $75.289M, slower than sales growth; gross profit increased to $69.342M from $59.774M, and gross margin expanded to 46.4% from 44.3%. Operating expenses were $57.984M versus $54.805M, while operating income more than doubled to $11.358M from $4.969M (7.6% operating margin versus 3.7%). Net income increased to $9.152M from $4.427M. Other income was $1.245M versus $1.705M, and the effective tax rate declined to 27.4% from 33.7%, mainly reflecting larger tax benefits from equity-award vesting and option exercises.

For H1, revenue rose 10.5% to $288.677M from $261.268M. Cost of revenue was $155.743M versus $145.796M; gross profit grew to $132.934M from $115.472M, with gross margin of 46.0% versus 44.2%. Operating expenses were $111.737M versus $105.972M, and operating income increased to $21.197M from $9.500M. Net income was $17.263M versus $8.026M. Other income declined to $2.723M from $3.159M. The H1 effective tax rate fell to 27.8% from 36.6%, although tax provision increased to $6.657M from $4.633M; the rate reduction reflected equity-related tax benefits and losses at a newly established India entity.

Revenue mix and customer trends

In Q2, U.S. revenue was $122.759M from $110.712M, and Europe revenue was $26.582M from $24.351M. U.S. growth was led by CNC machining and injection molding demand from aerospace and defense customers, together with market-driven price increases. A stronger euro added $0.4M to Q2 international revenue. H1 U.S. revenue increased $23.9M (11.3%) and Europe increased $3.5M (7.0%); foreign exchange, mainly a stronger pound and euro, added $2.6M to international revenue.

Q2 revenue by product line: Injection Molding $53.625M from $47.415M; CNC Machining $70.360M from $61.945M; 3D Printing $20.667M from $21.215M; Sheet Metal $4.462M from $4.303M; Other $0.227M from $0.185M. CNC machining and injection molding drove growth, while 3D printing declined.

Unique customer contacts fell 5.3% in Q2 to 20,630 from 21,775, while revenue per contact rose 16.7% to $7,239 from $6,203. For H1, contacts declined 6.2% to 31,069 from 33,136, while revenue per contact increased to $9,291 from $7,885. Management links this pattern to customer mix and a deliberate focus on larger, more strategic customers.

Costs, investment and strategy

Higher H1 production volume increased raw-material and production costs by $5.1M and personnel costs by $5.0M (including headcount, overtime and contract labor); equipment and facility costs declined $0.2M. Marketing and Sales expense rose $2.0M, while R&D fell $0.5M and G&A increased $1.1M. Restructuring and transformation costs were $0.924M in Q2 and $2.345M in H1, versus none in 2025, primarily for professional services and severance. German facility closures contributed $0.937M of Q2 exit/disposal costs, including a $0.9M write-down of an abandoned facility right-of-use asset. Management expects savings to be reinvested mainly in technology, automation and digital capabilities. Its broader strategy emphasizes customer experience, innovation, production expansion and operational efficiency, including AI applications in pricing, sourcing, inspection, toolpath verification and software development.

Stock-based compensation was $4.088M in Q2 versus $4.259M, and $7.307M in H1 versus $8.251M.

Cash flow and liquidity

H1 operating cash flow increased to $33.0M from $29.0M. Higher net income and deferred taxes supported the increase, partly offset by $11.7M of adverse year-over-year changes in operating assets, liabilities and other items. Operating cash flow included stock-based compensation of $7.3M versus $8.3M and depreciation and amortization of $16.2M versus $17.3M.

Investing cash outflow was $12.0M versus $3.6M, including capital expenditures/net purchases of property, equipment and other capital assets of $8.5M versus $2.7M, and $3.5M of net marketable-security purchases. Financing cash outflow was $3.9M versus $25.2M; H1 2026 included $5.0M of share repurchases, $6.0M of shares withheld for equity-award taxes and $7.3M of equity-plan proceeds. Cash and cash equivalents were $127.9M at June 30, 2026, up $17.1M from year-end 2025. Management expects cash and operating cash generation to cover working-capital and capital-expenditure needs for at least 12 months. No material changes to critical accounting estimates were reported.

Foreign-currency risk

PRLB has unhedged foreign-currency exposure because international revenue, production and sourcing costs, and operating expenses are denominated primarily in British pounds and euros. A stronger U.S. dollar—or a stronger pound relative to the euro—could adversely affect operating results and cash flows. The company expects its exposure to increase as it expands internationally. Management estimates that a hypothetical 10% adverse exchange-rate movement would generally not materially affect financial position, but could materially affect operating results.

Foreign-currency losses were $0.2M in Q2 2026, compared with gains of $0.5M in Q2 2025; for H1 2026, losses were $0.2M, compared with gains of $0.5M in H1 2025. Separately, currency movements favorably affected consolidated revenue by $0.4M in Q2 2026 and $2.6M in H1 2026, versus the corresponding 2025 periods.

Controls and Procedures

Management, including the CEO and CFO, concluded that disclosure controls and procedures were effective as of the end of the reporting period, providing reasonable assurance that required information was accurately recorded, processed, reported on time, and communicated to support timely disclosure decisions. No changes during the period materially affected, or were reasonably likely to materially affect, internal control over financial reporting.

This section reported no financial metrics or material business developments.

Risk Factors

PRLB reported no material changes to the risk factors described in its Annual Report on Form 10-K for the year ended December 31, 2025. This section provides no new financial metrics, business developments, or industry-specific risks.

Insider Trading Arrangements

On June 6, 2026, CFO Daniel Schumacher adopted a Rule 10b5-1 trading plan covering sales of up to 10,000 shares of company common stock related to his vested restricted stock units. The plan is scheduled to take effect on September 4, 2026, and expire on June 3, 2027, or earlier if all authorized sales are completed. No other directors or officers adopted, modified, or terminated a Rule 10b5-1 plan or non-Rule 10b5-1 trading arrangement during the three months ended June 30, 2026.

This section reports no financial results or material business developments.